ArticleJournal of traditional and complementary medicine2026
Geniposide activates the transcription of Ndufs8 and enhances PD-L1 blockade for inhibiting growth of osteosarcoma.
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Geniposide, a key bioactive component of Gardenia jasminoides, is an iridoid glycoside known for its therapeutic potential in various diseases characterized by oxidative stress or inflammation, including atherosclerosis, brain disorders, and diabetes. However, its effects on osteosarcoma and the underlying mechanisms are unknown. Therefore, we explored the impact of geniposide on osteosarcoma growth through proteomic analysis. After subcutaneous tumorigenesis of osteosarcoma cells proteomic alterations were analyzed. GO and KEGG pathway analyses were performed to identify enriched pathways and critical proteins. Immunohistochemistry and Western blotting were conducted to measure the protein expression of AMPK, SIRT1, OVOL3, and Ndufs8. Flow cytometry, CCK-8, and colony formation assays were employed to assess osteosarcoma growth. ELISA assay was utilized to measure alterations in pyruvate, lactate, and ATP following geniposide treatment. ChIP were performed to confirm OVOL3 transcriptionally regulates Ndfus8. The results demonstrated that geniposide inhibited osteosarcoma growth by 45-65 % in tumor weight, with proteomic data revealing oxidative phosphorylation as the critical pathway. Geniposide reduced Ki-67 and PCNA expression by 30-55 %, while increasing apoptosis rates by 2.5-fold. Mechanistically, Ndufs8 was upregulated 1.8-2.3-fold by geniposide, enhancing ROS levels by 40-60 % and suppressing osteosarcoma cell viability by 50-70 %. Additionally, geniposide suppressed PD-L1 expression by 40-50 % and synergized with PD-L1 blockade. These findings reveal that geniposide inhibits osteosarcoma through dual mechanisms: Ndufs8-mediated oxidative phosphorylation activation and PD-L1/PD-L1 axis suppression, offering a novel therapeutic strategy. These findings suggest that geniposide is a promising therapeutic agent for osteosarcoma and may enhance the efficacy of immunotherapy combined with PD-L1 blockade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.